Evidence map›Paper›PMID 24043763›Full record

ArticleThe Journal of experimental medicine2013

Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF.

Martin Guilliams, Ismé De Kleer, Sandrine Henri, Sijranke Post, Leen Vanhoutte, Sofie De Prijck, Kim Deswarte, Bernard Malissen, Hamida Hammad, Bart N Lambrecht

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04400929 (Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial), which is not on this map. Cited by 774 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
774citing papers in PubMed, 1 pooled it
48.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04400929 phase2completednot on this mapstarted 2020, after this paper: background citation

Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial

TypeinterventionalSponsorSingapore General HospitalRan2020 to 2022Enrolled2ConditionsCOVID, Sars-CoV2, ARDS, HumanArmsSargramostim, Normal Saline 0.9%
3 · Its place in the literature

Who cites it

774 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,217 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

714 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Martin GuilliamsLaboratory of Immunoregulation and Mucosal Immunology, VIB Inflammation Research Center, 9050 Ghent, Belgium.
Ismé De Kleer
Sandrine Henri
Sijranke Post
Leen Vanhoutte
Sofie De Prijck
Kim Deswarte
Bernard Malissen
Hamida Hammad
Bart N Lambrecht
Ghent University Hospital · BEVIB-UGent Center for Inflammation Research · BEAix-Marseille Université · FRCentre d’Immunologie de Marseille-Luminy · FRErasmus MC · NLInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue-resident macrophages can develop from circulating adult monocytes or from primitive yolk sac-derived macrophages. The precise ontogeny of alveolar macrophages (AMFs) is unknown. By performing BrdU labeling and parabiosis experiments in adult mice, we found that circulating monocytes contributed minimally to the steady-state AMF pool. Mature AMFs were undetectable before birth and only fully colonized the alveolar space by 3 d after birth. Before birth, F4/80(hi)CD11b(lo) primitive macrophages and Ly6C(hi)CD11b(hi) fetal monocytes sequentially colonized the developing lung around E12.5 and E16.5, respectively. The first signs of AMF differentiation appeared around the saccular stage of lung development (E18.5). Adoptive transfer identified fetal monocytes, and not primitive macrophages, as the main precursors of AMFs. Fetal monocytes transferred to the lung of neonatal mice acquired an AMF phenotype via defined developmental stages over the course of one week, and persisted for at least three months. Early AMF commitment from fetal monocytes was absent in GM-CSF-deficient mice, whereas short-term perinatal intrapulmonary GM-CSF therapy rescued AMF development for weeks, although the resulting AMFs displayed an immature phenotype. This demonstrates that tissue-resident macrophages can also develop from fetal monocytes that adopt a stable phenotype shortly after birth in response to instructive cytokines, and then self-maintain throughout life.

Indexed as

AnimalsCell DifferentiationFemaleGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem CellsHomeostasisImmunophenotypingLungMacrophages, AlveolarMiceMice, KnockoutMonocytesPhenotypeWhole-Body IrradiationGranulocyte-Macrophage Colony-Stimulating Factor

Identifiers

PMID24043763
PMCPMC3782041
OpenAlexW2100646399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.